Background: Androgen ablation is often used in addition to low-dose-rate brachytherapy in the treatment of prostate cancer, particularly for disease with adverse features. We report a single ...

Treatment of metastatic prostate cancer with androgen ablation often elicits dramatic tumor regressions, but the response is rarely complete, making clinical recurrence inevitable with time.

More than 20,000 American men die every year from prostate cancer. Most of them die because their cancer fails androgen ablation therapy, a.k.a. chemical castration. It is well known that prostate ...

Recently, two potential benefits of the use of transient androgen ablation prior to external radiation have been identified. First, there may be some synergy between the apoptotic response induced by ...

Disease progression that has been observed in a substantial proportion of patients despite androgen ablation, can arise from many factors, such as the presence of ...

As the authors note in this report, a longer time to PSA progression seems to occur after two courses of androgen ablation, which might correspond to the time for the evolution of resistance to ...

Early stage prostate cancer (PCa) is responsive to androgen ablation therapy, but invariably recurs as castration-resistant and highly aggressive. Neuroendocrine ... Prostate cancer is the leading ...

Treatment of patients with locally advanced prostate cancer (Stage T3 or T4) is radiation therapy with or without HDR interstitial therapy, androgen ablation plus external radiation or radical ...

Table I displays demographic, disease and treatment information for the whole cohort based on androgen ablation. Table II displays the characteristics of the EBRT and no-EBRT subgroups.